Tumor Biology

, Volume 37, Issue 7, pp 9255–9262 | Cite as

Involvement of CASP3 promoter polymorphism (−1337 C > G) in the development and progression of non-small cell lung cancer

  • Jamsheed Javid
  • Rashid Mir
  • Alpana Saxena
Original Article


Downregulation of CASP3 gene expression has been observed to be associated with various malignancies, and promoter polymorphisms in the CASP3 gene may have a great impact on the CASP3 transcriptional activity. The present study aimed to analyze the possible impact of the CASP3 (−1337 C > G, rs1405937) polymorphism on the expression profile of CASP3 gene and ultimately its association in the development of non-small cell lung cancer. A case–control study of 100 non-small cell lung cancer patients and 100 cancer free healthy controls was conducted, wherein genotype and expression profile of CASP3 gene were evaluated using serum DNA and serum RNA, respectively, by primer-introduced restriction fragment analysis and real-time PCR techniques. Compared to the CASP3 CC genotype, odds ratio of 11.1 was found to be associated to the homozygous GG genotype with more than sixfold decrease of CASP3 gene expression in non-small cell lung cancer patients. Significant trend of decrease in caspase 3 expression was observed with the increase in severity of the disease. Patients with CASP3 (−1337GG) genotype had significantly shorter overall survival compared to CASP3 (−1337CC) genotype carriers. In addition, significantly poor overall survival was also reflected by patients with higher fold decrease in CASP3 gene expression. CASP3 (−1337 GG) genotype was found to be associated with significantly lower CASP3 gene expression especially among patients with advanced status of the disease, suggesting that CASP3 (−1337C > G) polymorphism may be involved in the development and progression of non-small cell lung cancer.


Non-small cell lung cancer CASP3 (−1337 C > G) polymorphism CASP3 gene expression 



Non-small cell lung cancer


Caspase 3 gene


Squamous cell carcinoma





The authors specially thank all of the patients who participated in this study.

Conflicts of interest



  1. 1.
    Estimated cancer incidence, mortality and prevalence Worldwide in 2012. GLOBOCAN 2012.
  2. 2.
    Lung cancer: survival rates and prognosis. National cancer Institute. 2012. -survival-prognosis. Accessed 10 May 2012.
  3. 3.
    Levi F. Cancer prevention: epidemiology and perspectives. Eur J Cancer. 1999;35(14):1912–24.CrossRefPubMedGoogle Scholar
  4. 4.
    Schottenfeld D, Fraumeni JF. Cancer epidemiology and prevention 3rd ed. OUP USA 2006 pp 638–658.Google Scholar
  5. 5.
    Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39:605–13.CrossRefPubMedGoogle Scholar
  6. 6.
    MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst. 2004;96:1866–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Hu Z, Li C, Chen K, Wang L-E, Wei Q. Single nucleotide polymorphisms in selected apoptotic genes and BPDE-induced apoptotic capacity in apparently normal primary lymphocytes: a genotype-phenotype correlation analysis. J Cancer Epidemiol. 2008;2008:147905.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chang MW, Lo JM, Juan HF, Chang HY, Chuang CY. Combination of RGD compound and low-dose paclitaxel induces apoptosis in human glioblastoma cells. PLoS One. 2012;7(5), e37935.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wang JX, Zheng S. Caspase 3 and survivin expression in pediatric neuroblastoma and their roles in apoptosis. Chin Med J. 2004;117:1821–4.PubMedGoogle Scholar
  10. 10.
    Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002;21:8843–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Isobe N, Onodera H, Mori A, Shimada Y, Yang W, Yasuda S, et al. Caspase 3 expression in human gastric carcinoma and its clinical significance. Oncology. 2004;66(3):201–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001;61(3):1227–32.PubMedGoogle Scholar
  13. 13.
    Xu M, Xia LP, Fan LJ, Xue JL, Shao WW, Xu D. Livin and caspase-3 expression are negatively correlated in cervical squamous cell cancer. Eur J Gynaecol Oncol. 2013;34(2):152–5.PubMedGoogle Scholar
  14. 14.
    Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res. 2001;61(1):348–54.PubMedGoogle Scholar
  15. 15.
    Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H, et al. Involvement of CPP32/Yama(−like) proteases in Fas-mediated apoptosis. Cancer Res. 1996;56(8):1713–8.PubMedGoogle Scholar
  16. 16.
    Silke J, Ekert PG, Day CL, Hawkins CJ, Baca M, Chew J, et al. Direct inhibition of caspase 3 is dispensable for the anti-apoptotic activity of XIAP. EMBOJ. 2001;20(12):3114–23.CrossRefGoogle Scholar
  17. 17.
    Widiana IK, Wibawa-M I, Siki-Kawiyana K, Sutirta-Yasa I. Changes of mRNA Caspase-3 after first cycle of chemotherapy as biomarker associate to chemotherapy negative response in locally advanced breast cancer. Bali Med J. 2015;4(2):53–5.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Medical Laboratory Technology, Faculty of Applied Medical SciencesUniversity of TabukTabukSaudi Arabia
  2. 2.Department of BiochemistryMaulana Azad Medical College and Associated HospitalsNew DelhiIndia

Personalised recommendations